Imetelstat: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Imetelstat. Educational only — not medical advice.
Labeled uses
RYTELO is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).
Source: FDA labeling via NIH DailyMed (set b0fab7ca…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.